Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tmo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Thermo Fisher Scientific Inc. (TMO) measures how much investors pay for each dollar of the company's trailing earnings. TMO's current PE ratio of 25.64x is calculated by dividing its stock price of $472.80 by its TTM earnings per share of $18.44. −21.3% discount vs 5Y avg 32.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%30.8x
MedianQ3 · 75%52.6x
Max
At 25.64x, TMO's current P/E is lower than in 25% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Thermo Fisher Scientific Inc.You TMO | $175.7B | 25.64x | -18.2% | $18.44 |
 Agilent Technologies, Inc. A | $38.3B | 31.79x | +1.5% | $4.60 |
 Abbott Laboratories ABT | $158.6B | 33.55x | +7.1% | $3.73 |
 Amgen Inc. AMGN | $188.7B | 22.84x | -27.1% | $14.33 |
 AstraZeneca PLC AZN | $288.4B | 26.53x | -15.3% | $6.62 |
 Danaher Corporation DHR | $130.4B | 44.80x | +43.0% | $5.11 |
 IQVIA Holdings Inc. IQV | $30.6B | 28.49x | -9.1% | $7.91 |
Industry Average 6 peers with valid PE | — | 31.33x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 32.34x | $17.92 | +3.1% | |
2024-12-31 FY2024 | 31.37x | $16.58 | -8.2% | |
2023-12-31 FY2023 | 34.18x | $15.53 | +10.0% | |
2022-12-31 FY2022 | 31.06x | $17.73 | -8.7% | |
2021-12-31 FY2021 | 34.03x | $19.61 | +17.6% | |
2020-12-31 FY2020 | 28.93x | $16.10 | -17.7% | |
2019-12-31 FY2019 | 35.16x | $9.24 | +14.8% | |
2018-12-31 FY2018 | 30.62x | $7.31 | -9.2% | |
2017-12-31 FY2017 | 33.71x | $5.63 | +22.3% | |
2016-12-31 FY2016 | 27.55x | $5.12 | -3.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Thermo Fisher Scientific Inc. (TMO) measures how much investors pay for each dollar of the company's trailing earnings. TMO's current PE ratio of 25.64x is calculated by dividing its stock price of $472.80 by its TTM earnings per share of $18.44.
Frequently asked questions
TMO pe ratio · 6 questionsTMO's current PE ratio is 25.64x as of 2026-06-08, based on a stock price of $472.80 and TTM EPS of $18.44. Data sourced from Financial Modeling Prep via TMO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Thermo Fisher Scientific Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08